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 Abstract 
Kisspeptin is the peptide product of the KiSS-1 gene and the endogenous agonist for 
the GPR54 receptor. Recent evidence suggests the kisspeptin/GPR54 system is a key 
regulator of the reproductive system. We examined the effect of 
intracerebroventricular (i.c.v.) and peripheral administration of the active kisspeptin 
fragment, kisspeptin-10, on circulating gonadotropins and total testosterone levels in 
adult male rats. The effect of kisspeptin-10 in-vitro on the release of hypothalamic 
peptides from hypothalamic explants and gonadotropins from anterior pituitary 
fragments was also determined. The i.c.v. administration of kisspeptin-10 dose-
dependently increased plasma luteinizing hormone (LH) and increased plasma follicle 
stimulating hormone (FSH) and total testosterone at 60 mins post-injection. In a 
separate study investigating the time course of this response, i.c.v. administered 
kisspeptin-10 (3nmol) significantly increased plasma LH at 10, 20 and 60 mins, FSH 
at 60 mins and total testosterone at 20 and 60 mins post-injection. Kisspeptin-10 
stimulated the release of luteinizing hormone releasing hormone (LHRH) from in-
vitro hypothalamic explants. Peripheral administration of kisspeptin-10 increased 
plasma LH, FSH and total testosterone. However, doses of 100-1000nM kisspeptin-10 
did not influence LH or FSH release from pituitary fragments in-vitro. Kisspeptin 
therefore potently stimulates the hypothalamic- pituitary-gonadal (HPG) axis. These 
effects are likely to be mediated via the hypothalamic LHRH system.  
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Introduction 
Kisspeptin is a 54 amino acid peptide encoded by the tumour suppressor gene KiSS-1 
(1-4). Kisspeptin is thus also known as ‘metastin’ because of its antimetastatic 
properties (4,5). Using quantitative polymerase chain reaction, KiSS-1 mRNA 
expression has been demonstrated in the placenta and throughout the central nervous 
system (CNS), including the hypothalamus (3). Endogenous forms of kisspeptin 54, 
14 and 13 amino acids in length have been isolated from human placenta. The 
common C terminal decapeptide shared by these forms, kisspeptin-10, is secreted by 
cultured human trophoblasts (6). In humans, circulating kisspeptin levels are 7000-
fold higher than basal levels during the third trimester of pregnancy (7). 
All kisspeptin fragments, including kisspeptin-10, have a similar affinity and efficacy 
for the previously orphan G-protein-coupled receptor, GPR54 (1). GPR54 was 
originally isolated from rat brain (8) and is highly expressed in the rat and human 
CNS and peripheral tissues (1,8). GPR54 receptor mRNA is expressed in several rat 
brain regions, with highest expression in the hypothalamus and amygdala. Within the 
hypothalamus, GPR54 mRNA is highly concentrated in the arcuate nucleus, the 
lateral hypothalamic area and the dorsomedial nucleus (8). In the periphery it is highly 
expressed in the pituitary, placenta and pancreas (1,3). Peripheral administration of 
kisspeptin-10 increases  plasma oxytocin levels in female rats (1). 
Recent reports suggest that the kisspeptin/GPR54 system is a key regulator of the 
reproductive system. GPR54 deficient (GPR54-/-) mice have abnormal sexual 
development and low circulating gonadotropin concentrations (9,10). In humans, 
GPR54 mutations have been shown to cause isolated hypogonadotropic 
hypogonadism in two different consanguineous families (10,11). GPR54 thus appears 
essential for normal gonadotropin secretion and the regulation of puberty. 
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 To investigate the role of the kisspeptin/GPR54 system in the hypothalamic-pituitary 
gonadal axis (HPG) axis, we examined the effect of central and peripheral 
administration of kisspeptin-10 on circulating gonadotropins and total testosterone 
levels in adult male rats. During the preparation of this manuscript, two independent 
groups demonstrated findings in accord to those observed in the present study. Matsui 
et al revealed that subcutaneously (s.c.) administered kisspeptin-54 increases plasma 
gonadotropins in male and prepubertal female rats (12) and Gottsch et al showed that 
i.c.v. administration of kisspeptin-10 or kisspeptin-54 increases plasma LH and FSH 
in male mice (13). Here we investigate the time course of i.c.v. effects of kisspeptin-
10 on circulating gonadotropins in another species, the male rat, additionally 
determining the effects on plasma testosterone levels. We have also investigated the 
time course of the effects on plasma gonadotropins and testosterone of intraperitoneal 
(i.p.) injections of kisspeptin-10 in the male rat, a different route of peripheral 
administration to that previously studied. In addition, to investigate whether the 
actions of kisspeptin-10 are mediated via the hypothalamic LHRH system, we have 
examined the effect of kisspeptin-10 on the release of LHRH from hypothalamic 
explants. We have also investigated the effects of kisspeptin-10 on gonadotropin 
secretion from anterior pituitary fragments.  
GPR54 and kisspeptin mRNA have been found in several hypothalamic nuclei 
involved in appetite control. Several hormones and neuropeptides are involved in the 
regulation of both the HPG axis and energy balance. The absence of the adipocyte 
hormone leptin suppresses the HPG axis (14). Central administration of the 
hypothalamic neuropeptides galanin-like peptide (GALP) or prolactin releasing 
peptide (PrRP) influence both feeding behaviour and the gonadotropic axis (15-17). 
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We have therefore investigated the effect of i.c.v. administered kisspeptin-10 on food 
intake in three models of feeding behaviour.  
 
Methods 
Materials 
Kisspeptin-10 was purchased from Peptide Institute Inc (Osaka, Japan). Reagents for 
basal hypothalamic explant experiments and pituitary fragments experiments were 
supplied by BDH (Poole, Dorset, UK). 
 
Animals 
Male Wistar rats (Specific pathogen free, Charles River, UK) weighing 250-300g 
were maintained in individual cages for cannulation and similar rats weighing 200-
250g were caged in groups of five for use in peripheral studies and in hypothalamic 
and pituitary explant experiments. All animals were maintained under controlled 
temperature (21-23oC) and light (12 hrs light, 12 hrs dark, lights on at 07.00h) with ad 
libitum access to food (RM1 diet, SDS UK Ltd.) and water, unless otherwise 
specified.  
All animal procedures were conducted under the British Home Office Animals 
Scientific Procedures Act 1986 (Project Licence 70/5516) and in accordance with 
accepted standards of the local ethical review committee.   
 
Intracerebroventricular cannulation and injections 
Animals were implanted with permanent 22-gauge stainless steel i.c.v. cannulae 
projecting to the third cerebral ventricle (co-ordinates; 0.8mm posterior to bregma on 
the midline and implanted 6.5mm below the outer surface of the skull) as previously 
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described (18). Following a seven-day recovery period, the animals were acclimatised 
to the injection procedure and to the guillotine apparatus to minimise the metabolic 
consequences of stress on the study day. Only animals with correct cannula 
placement, as confirmed by a sustained drinking response to i.c.v. angiotensin II 
(150ng/rat), were included in the studies. 
All studies were carried out in the early light phase (08.00h – 11.00h) unless 
otherwise specified.  Peptides were dissolved in 0.9% saline and administered in a 5μl 
volume via a stainless steel injector projecting 0.5mm beyond the tip of the cannula.   
The injector was connected by polyethylene tubing (id, 0.5 mm; od, 1 mm) to a 
Hamilton syringe (Reno, NV, USA) in a syringe pump set to dispense 5μl 
solution/minute.  
 
Study 1(i) Dose-response of i.c.v. kisspeptin-10 on the hypothalamic-pituitary-
gonadal axis.  
Groups of rats (n =10-11/group) were i.c.v. injected with either 0.9% saline or 
kisspeptin-10 at 0.1, 0.3, 1 or 3nmol. At 60 mins following injection, rats were 
decapitated and trunk blood collected into lithium heparin tubes containing 0.6mg 
aprotinin (Bayer Corp., Haywards Heath, UK). Plasma was separated by 
centrifugation, frozen on dry ice and stored at –20oC until measurement of LH, FSH 
and total testosterone. 
Effect of i.c.v. administration of kisspeptin-10 on behaviour 
Behaviour was observed for 1 hr in the saline- and 3nmol kisspeptin-treated groups. 
Rats (n = 7-8/group) were observed continuously for 1 hr post i.c.v. injection by 
observers blinded to the experimental treatment. Behaviour was classified, as 
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previously described, into seven different categories: feeding, drinking, grooming, 
rearing (defined as stationary with front paws elevated), head down (defined as 
stationary with all four paws on the cage bottom), locomotion (defined as moving 
around the cage, with all four paws moving), or sleeping (19). Each rat was observed 
for 15 sec every 5 min during the test session. This 15-sec period was further divided 
into three 5-sec periods, and the behaviour of the rat was scored in each section of the 
time period. Each rat had a total of 36 behaviours recorded per hr.  
 
Study 1(ii) Time course of effect of i.c.v. kisspeptin-10 on the hypothalamic-
pituitary-gonadal axis.  
Groups of rats (n =8-10/group) were i.c.v. injected with either 0.9% saline or 
kisspeptin-10 (3nmol). At 10, 20 and 60 mins following injection, rats were 
decapitated, trunk blood collected and stored as above until measurement of LH, FSH 
and total testosterone. We have previously used 10, 20 and 60 minute time points to 
investigate changes in plasma LH and FSH following i.c.v. administration of 
prolactin-releasing peptide (20).  
 
Study 2. Effect of kisspeptin-10 on hypothalamic releasing hormones 
The static incubation system method used was as previously described (21). Male 
Wistar rats were killed by decapitation and the whole brain immediately removed.  
The brain was mounted with ventral surface uppermost and placed in a vibrating 
microtome (Microfield Scientific Ltd., Dartmouth, UK).  A 1.7mm slice was taken 
from the basal hypothalamus, to include the medial preoptic area (MPOA), and 
incubated in individual chambers containing 1ml of artificial cerebrospinal fluid 
(aCSF), (20mM NaHCO3, 126mM NaCl, 0.09mM Na2HPO4, 6mM KCl, 1.4mM 
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CaCl2, 0.09mM MgSO4, 5mM glucose, 0.18mg/ml ascorbic acid and 100ug/ml 
aprotinin) equilibrated with 95% O2 and 5% CO2.  The tubes were placed on a 
platform in a water bath maintained at 37oC.  After an initial 2 hr equilibration period, 
the hypothalami were incubated for 45 mins in 600μl aCSF (basal period) before 
being incubated with kisspeptin-10 at 1, 10 or 100nM for 45 minute test period (n=13-
22/dose).  The viability of the tissue was verified by a final 45 minute exposure to 
56mM KCl; isotonicity was maintained by substituting K+ for Na+.  Explants not 
showing significant release following KCl (<10%) were excluded from the analysis.  
At the end of each period, the aCSF was removed and frozen at –20oC until 
measurement of LHRH, oxytocin and galanin by radioimmunoassay (RIA). Oxytocin 
and galanin have been shown to be involved in reproductive function (22,23). 
 
Study 3. Effect of peripheral administration of kisspeptin-10 on the 
hypothalamic-pituitary-gonadal axis 
(i) Rats (n=9-11/group) received an intraperitoneal (i.p.) injection of 0.5ml 0.9% 
saline for three days to acclimatise them to the injection procedure and also 
underwent sham decapitation for 2 days prior to the study day. On the following day, 
rats were i.p. injected with either 0.9% saline, kisspeptin-10 at 10, 30, 100nmol, or 
30nmol LHRH as a positive control. At 20 mins following injection, rats were 
decapitated and trunk blood was collected and stored as above until measurement of 
LH, FSH and total testosterone. 
(ii) Rats (n=8-10/group) were i.p. injected as described above in 3(i). At 60 mins 
following injection, rats were decapitated, trunk blood collected and stored as above.  
 8
(iii) The results of study 3(ii) did not show an increase in plasma FSH that may have 
been expected following the i.c.v. studies. Study 3(ii) used i.p. injections of 
kisspeptin-10 up to 100nmol. To further investigate the effect of peripheral 
kisspeptin-10 on FSH, rats (n=9-11/group) were treated with saline or 300nmol 
kisspeptin-10 and decapitated at 60 min following injection. Trunk blood was 
collected and stored as above. 
 
Study 4. Effect of kisspeptin-10 on gonadotropin release from anterior pituitary 
fragments 
The effects of kisspeptin-10 on pituitary LH and FSH release were determined using 
anterior pituitary segments. The method was a modification of that previously 
described (24).  Rats were decapitated and anterior pituitary glands were harvested 
immediately then divided into 4 pieces of approximately equal size.  The segments 
were randomly placed (1 segment/well) in the wells of a 48-well tissue culture plate 
(Nunc International, Denmark) and incubated in 500μl of aCSF as detailed above.  
The anterior pituitary segments were maintained at 37oC in a humidified environment 
saturated with 95% O2 and 5% CO2 for 2 hr with the medium changed after 1hr and 
2hr.  The segments were then incubated in aCSF alone (control), kisspeptin-10 at 100 
or 1000nM, or 100nM LHRH as a positive control for 4hr (n=24/group).  At the end 
of this period, the aCSF was collected and stored at –20oC until RIA for LH.  As no 
dose of kisspeptin-10 showed a significant effect on LH release, only the aCSF alone, 
kisspeptin-10 1000nM and LHRH 100nmol samples were assayed for FSH. 
 
 
 9
Study 5(i). ICV kisspeptin-10 on food intake in fed animals during the early light 
phase 
Feeding experiments were carried out in i.c.v. cannulated rats as previously described 
(25). Ad libitum fed rats were i.c.v. injected between 08.30h and 09.30h with 0.9% 
saline, kisspeptin-10 at 0.3, 1, or 3nmol or 5nmol NPY (as a positive control)  (n =8-
11/group) . Rats were returned to their home cages with a pre-weighed amount of 
chow and free access to water. The remaining food was reweighed at 1, 2, 4, 8 and 24 
hrs post injection. A dose of 3nmol kisspeptin-10 was the highest used as pilot studies 
showed higher doses (10nmol) produced adverse behavioural effects (data not 
shown). 
Study 5(ii). ICV kisspeptin-10 on food intake in fasted animals during the early 
light phase 
Rats fasted overnight were i.c.v. injected between 08.30h and 09.30h with 0.9% 
saline, kisspeptin-10 at 0.3, 1, or 3nmol or 3nmol NDP-alpha-melanocyte stimulating 
hormone (NDP-MSH) (as a positive control) (n=8-10/group) . Rats were returned to 
their home cages with a pre-weighed amount of chow and free access to water. The 
remaining food was reweighed at 1, 2, 4, 8 and 24 hrs post injection.  
Study 5 (iii). ICV kisspeptin-10 on food intake in fed animals during the early 
dark phase 
To check whether kisspeptin-10 effects food intake during the natural rat feeding 
period, ad-libitum fed rats were i.c.v. injected with 0.9% saline, kisspeptin-10 at 
3nmol or 3nmol NDP-MSH, (as a positive control) immediately before the onset of 
dark phase (19.00h)(n=8-10/group). Rats were returned to their home cages with a 
pre-weighed amount of chow and free access to water. The remaining food was 
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reweighed at 1, 2, 4, 8 and 24 hrs post injection. Only 3nmol kisspeptin-10, the highest 
dose previously used, was administered in this study as no effect on appetite had been 
observed in 5(i) and 5(ii). 
 
Hormone assays 
LHRH was measured in aCSF by a sensitive and specific radioimmunoassay (RIA) 
(reagents and methods provided by Dr. H.M. Fraser, Medical Research Council 
Reproductive Biology Unit, Edinburgh, Scotland). Oxytocin  and galanin were 
measured by RIA as previously described (26,27). LH levels in plasma were assayed 
using reagents and methods provided by the NIDDK and the National Hormone and 
Pituitary Program (Dr. A. Parlow, Harbor University of CA, Los Angeles Medical 
Center, USA) as previously described (28). The intra- and inter- assay coefficients of 
variation were 8.2% and 13.6% respectively. Plasma FSH was measured by 
commercial immuno-radiometric assay (IDS Ltd, Boldon, UK) and total plasma 
testosterone by commercial Coat-a-Count assay kit (EURO/DPC Limited, Caernarfon, 
UK).  
 
Statistical analysis 
Results are shown as mean values ± SEM. Data from hypothalamic explant release 
experiments were compared by paired t-test between the basal period and test period.  
Data from the i.c.v. time-course study was compared by unpaired t-test between saline 
and kisspeptin-10 groups at each time point. Data from study 3(iii) was compared by 
unpaired t-test between saline and 300nmol kisspeptin-10 at the 60 minute time point. 
As behavioural observation data were not normally distributed, Kruskal-Wallis test 
was used for comparisons between treatment groups. All other in vivo and in vitro 
 11
study results were compared by analysis of variance (ANOVA) with post hoc 
Dunnett’s test (Systat, Evanston, IL). In all cases, p<0.05 was considered to be 
statistically significant. 
 
Results 
 
Study 1(i) Dose response of i.c.v. kisspeptin-10 on the hypothalamic-pituitary-
gonadal axis. 
Intracerebroventricular administration of kisspeptin-10 dose-dependently increased 
plasma LH and increased plasma FSH and testosterone 60 mins post injection. Plasma 
LH was significantly increased following i.c.v. injection of 1 and 3nmol kisspeptin-10 
(saline 0.3 ± 0.02ng/ml; 1nmol kisspeptin 5.0  ±  1.17ng/ml, 3nmol kisspeptin 9.4 ± 
1.85ng/ml, p<0.05, n=9-11/group) (Figure 1(i)A). Plasma FSH was significantly 
increased following i.c.v. injection of 1nmol kisspeptin-10 (saline 13.2  ± 1.45ng/ml; 
1nmol kisspeptin 23.8 ± 3.08ng/ml p<0.05, n=9-11/group). Plasma FSH was 
increased following i.c.v. injection of 0.3nmol and 3nmol kisspeptin-10 (0.3nmol 
kisspeptin 20.8 ± 3.35ng/ml, 3nmol kisspeptin 20.2 ± 2.9ng/ml), however this did not 
reach significance (Figure 1(i)B). Total plasma testosterone was significantly 
increased following i.c.v. injection of 0.1, 0.3, 1, and 3nmol kisspeptin-10 (saline 5.8 
± 0.72nmol/L; 0.1nmol kisspeptin 15.7 ± 2.98nmol/L, 0.3nmol kisspeptin 13.8 ± 
3.02nmol/L, 1nmol kisspeptin 21.9 ± 1.46nmol/L, 3nmol kisspeptin  21.2 ± 
1.16nmol/L, p<0.05, n=9-11/group) (Figure 1(i)C).  No significant differences in 
behaviour were observed following i.c.v. injection of 3nmol kisspeptin-10 over the 1 
hr observation period (Table 1). 
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Study 1(ii). Time course of i.c.v. kisspeptin-10 on the hypothalamic-pituitary-
gonadal axis.  
Intracerebroventricular injection of 3nmol kisspeptin-10 significantly increased 
plasma LH at 10 mins (saline 1.0 ± 0.08ng/ml; kisspeptin 1.7  ±  0.29ng/ml, p<0.05, 
n=9-10/group) and this effect was maintained at 20 mins (saline 0.8 ± 0.08ng/ml; 
kisspeptin 2.7 ± 0.48ng/ml, p<0.01, n=8-10/group) and 60 mins (saline 0.3 ± 
0.02ng/ml; kisspeptin 5.2  ±  1.13ng/ml, p<0.001, n=8-10/group) post-injection 
(Figure 1(ii)A).  Plasma FSH was significantly increased at 60 mins post-injection 
(saline 16.9  ± 1.46ng/ml; kisspeptin 34.4  ±  3.71ng/ml, p<0.001, n=8-10/group) 
(Figure 1(ii)B). In the previous i.c.v. dose response study, 3nmol kisspeptin-10 
increased plasma FSH at 60 mins, but this change did not reach statistical 
significance.  In this experiment the rise is statistically significant. This discrepancy 
may be due to variation between the different groups of animals or assay variation. 
Total plasma testosterone was significantly increased at 20 and 60 mins following 
injection (20 mins: saline 3.0 ± 0.27nmol/L; kisspeptin 6.4  ±  1.19nmol/L, p<0.05, 
n=8-10/group; 60mins: saline 4.1 ± 0.36 nmol/L; kisspeptin 14.2 ± 2.80nmol/L, 
p<0.01, n=8-10/group) (Figure 1(ii)C). 
 
Study 2. Effect of kisspeptin-10 on hypothalamic releasing hormones 
Administration of kisspeptin-10 to hypothalamic explants stimulated the release of 
LHRH at doses of 10 and 100nM (Figure 2). Kisspeptin did not significantly alter 
oxytocin or galanin release from hypothalamic explants (Table 2).  
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Study 3. Effect of peripheral administration of kisspeptin-10 on the 
hypothalamic-pituitary-gonadal axis 
(i) Peripheral injection of 100nmol kisspeptin-10 significantly increased plasma LH at 
20 mins post injection (saline 0.6 ± 0.06ng/ml; 100nmol kisspeptin 5.9 ± 1.55ng/ml, 
p<0.05, n=9-11/group) (Figure 3(i)A). Injection of 10 and 30nmol kisspeptin-10 also 
increased plasma LH, but these changes did not reach statistical significance. There 
was no effect on plasma FSH and total testosterone 20 mins post injection (Figures 
3(i) B & C).  
(ii) Peripheral injection of 10, 30 and 100nmol kisspeptin-10 did not increase plasma 
LH or FSH at 60 mins post-injection (Figure 3(ii) A & B). Similarly, peripheral 
administration of 30nmol LHRH did not significantly increase plasma LH or FSH at 
60 mins post injection. However, 30 and 100nmol kisspeptin-10 and 30nmol LHRH 
did significantly increase total plasma testosterone at 60 mins post injection (saline 
1.1 ± 0.39nmol/L; 30nmol kisspeptin 5.9 ± 1.21nmol/L, 100nmol kisspeptin 5.8 ± 
1.43nmol/L, 30nmol LHRH 5.8 ± 1.26nmol/L, p<0.05, n=8-10/group). The rise in 
total plasma testosterone produced by 30 and 100nmol kisspeptin-10 is of a similar 
magnitude to that induced by 30nmol LHRH (a 6-fold increase from saline control). 
(Figure 3(ii)C). 
(iii) Peripheral injection of 300nmol kisspeptin-10 significantly increased plasma LH, 
FSH and total testosterone at 60 mins post injection (LH: saline 0.5 ± 0.08ng/ml; 
300nmol kisspeptin 0.9 ± 0.16ng/ml, p<0.05. FSH: saline 12.9 ± 0.96ng/ml; 300nmol 
kisspeptin 16.9 ± 1.45ng/ml, p<0.05. Total testosterone: saline 3.4 ± 0.37nmol/L; 
300nmol kisspeptin 16.7 ± 6.18nmol/L, p<0.05, n=9-10/group). 
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Study 4. Effect of kisspeptin-10 on gonadotropin release from anterior pituitary 
fragments 
Kisspeptin-10 at doses 100 and 1000nM had no effect on the release of LH or FSH 
from in-vitro pituitary fragments (Table 3). This study was repeated twice.  
 
Study 5 (i).  Effect of ICV kisspeptin-10 on food intake in fed animals during the 
early light phase 
There were no differences in food intake between saline- and kisspeptin-treated 
groups at 1, 2, 4, 8 and 24 hrs post injection (Food intake at 0-2 hr shown in Figure 
4A). The positive control, 5nmol NPY, significantly increased food intake at 0-2 hrs. 
There were no differences in body weight change between saline and kisspeptin 
groups over the 24 hr period (Data not shown). 
Study 5(ii). ICV kisspeptin-10 on food intake in fasted animals during the early 
light phase 
There were no differences in food intake between saline- and kisspeptin-treated 
groups at 1, 2, 4, 8 and 24 hrs post injection (Food intake at 0-2 hr shown in Figure 
4B). The positive control, 3nmol NDP-MSH significantly decreased food intake at 0-
2 hrs. There were no differences in body weight change between saline and kisspeptin 
groups over the 24 hr period (Data not shown). 
Study 5(iii). ICV kisspeptin-10 on food intake in fed animals during the early 
dark phase 
There were no differences in food intake between saline- and kisspeptin-treated 
groups at 1, 2, 4, 8 and 24 hrs post injection (Food intake at 0-2 hrs shown in Figure 
4C). The positive control, 3nmol NDP-MSH significantly decreased food intake at 0-
 15
2 hrs. There were no differences in body weight change between saline and kisspeptin 
groups over the 24 hr period (Data not shown).  
 
Discussion 
We have demonstrated that kisspeptin-10, a fragment of the endogenous agonist for 
the GPR54 receptor, stimulates the HPG axis. Both i.c.v. and peripheral 
administration of kisspeptin-10 increased plasma LH, FSH and total testosterone.   
 
During the preparation of this manuscript, two reports were published which showed 
similar effects of kisspeptin on the HPG axis in accord with our own observations 
(12,13). We have shown kisspeptin-10 dose-dependently stimulates the release of 
LHRH from in-vitro hypothalamic explants, suggesting that kisspeptin stimulates the 
HPG axis via LHRH. Current evidence certainly suggests that kisspeptin operates 
upstream of LHRH. Female GPR54-/- mice can be induced to ovulate by exogenous 
administration of LHRH (10). Humans with GPR54 mutations have a suppressed 
HPG axis which is responsive to pulsatile administration of exogenous LHRH (10). 
The i.c.v. and peripheral actions of kisspeptin can be blocked by LHRH antagonists 
(12,13). It is possible that i.c.v. kisspeptin-10 influences intermediate neurons which 
regulate LHRH neurons. However, the GPR54 receptor has been localised to 
hypothalamic LHRH neurons in cichlid fish, suggesting a direct effect of kisspeptin 
on these neurons (29).  
 
GPR54 is expressed in the pituitary gland (1,3). It is possible peripherally 
administered kisspeptin acts directly on the pituitary to stimulate the release of LH 
and FSH. However, in the present study, kisspeptin had no effect on the release of LH 
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or FSH from male rat anterior pituitary fragments, while LHRH significantly 
increased LH and FSH release. GPR54 mRNA is also highly expressed within the 
arcuate nucleus, an area accessible to circulating hormones (8,30). The stimulation of 
the HPG axis seen following peripheral administration of kisspeptin may therefore be 
centrally mediated, possibly via GPR54 receptors in the arcuate nucleus. Experiments 
to investigate whether circulating kisspeptin enters the hypothalamus are required to 
further elucidate the mechanism of action of peripheral kisspeptin.  
  
Plasma LH levels were highest 60 mins following central administration of kisspeptin. 
However, following i.p. kisspeptin administration plasma LH levels were highest 20 
mins following injection and by 60 mins post injection only the highest kisspeptin 
dose (300nmol) caused any increase in plasma LH. Circulating kisspeptin may be 
degraded or cleared more rapidly than central kisspeptin thus reducing the duration of 
its effects. In contrast to our study, Matsui et al, observed raised plasma LH levels up 
to 2 hrs following peripheral kisspeptin administration (12). Matsui et al administered 
full length kisspeptin-54 subcutaneously. We have shown that the effects of i.p. 
kisspeptin-10 on LH release are short lived. This may be because kisspeptin-10 is 
inactivated or cleared more rapidly than kisspeptin-54. It is also possible that 
peripheral kisspeptin only has a short lived effect and the more sustained rise in LH 
seen with subcutaneous administration is due to a gradual release of peptide into the 
circulation from a subcutaneous depot. Further investigations into the 
pharmacokinetics of centrally and peripherally administered kisspeptins are required.      
 
GPR54 and kisspeptin mRNA have been detected in several hypothalamic nuclei 
involved in regulation of feeding.  GPR54 is expressed in the arcuate nucleus, lateral 
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hypothalamus, and the dorsomedial nucleus (8), and kisspeptin in the arcuate nucleus 
and the paraventricular nucleus (PVN) (13). We therefore studied the effects of acute 
i.c.v. administration of kisspeptin-10 on food intake in rats in three models: ad libitum 
fed rats in the early light phase, overnight fasted rats in the early light phase, and in ad 
libitum fed rats in the early dark phase. In all three models, kisspeptin-10 had no 
effect on food intake at any of the doses or time points studied (1, 2, 4, 8 and 24 hrs 
post injection). The highest i.c.v. dose of kisspeptin-10 (3nmol) had no effect on 
behaviour. Analysis of in behaviour is used to investigate obvious adverse effects. For 
example, an increase in grooming is often associated with the activation of central 
stress pathways (31). In addition, the physiological significance of any effect on 
appetite can be assessed by comparing changes to the Behavioural Satiety Sequence 
(32), a model describing observed changes in behaviour following normal satiation. 
Chemicals/peptides can suppress eating by producing adverse physiological effects 
such as pain, or illness, or may increase food intake as a secondary effect of increased 
arousal. We have found that centrally administered kisspeptin-10 does not appear to 
influence locomotive or sleeping behaviour and also has no effect on food intake or 
feeding behaviour.  Hypothalamic kisspeptin seems unlikely to play a major role in 
the regulation of appetite. 
 
In summary, we have described the effects of kisspeptin-10 on the HPG axis. Both 
central and peripheral administration of kisspeptin-10 increase plasma LH, FSH and 
total testosterone. Kisspeptin-10 stimulated the release of LHRH from hypothalamic 
explants. However, kisspeptin-10 had no effect on LH or FSH release from pituitary 
fragments, suggesting that peripheral kisspeptin stimulates the HPG axis via the 
hypothalamus. Further studies are required to define the physiological importance of 
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kisspeptin in the regulation of the HPG axis. The chronic effects of kisspeptin 
administration on the HPG axis and possible changes in central and peripheral 
kisspeptin expression in models of disrupted HPG activity would be particularly 
interesting to investigate.  
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Figure Legends 
 
Figure 1(i). The effect of i.c.v. saline (0) or kisspeptin-10 (0.1, 0.3, 1, 3nmol) on  
plasma levels of (A) LH, (B) FSH and (C) total testosterone in male Wistar rats at 60 
mins post injection. Significance is indicated by * p<0.05 vs saline control. n=9-
11/group. 
 
Figure 1(ii). The effect of i.c.v. saline or kisspeptin-10 (3nmol) at 10, 20 and 60mins 
following injection on plasma levels of (A) LH, (B) FSH and (C) total testosterone in 
male Wistar rats. Striped bar indicates saline and hatched bar indicates kisspeptin. 
Significance is indicated by * p<0.05, ** p<0.01, *** p<0.001 vs saline control. n=8-
10/group.  
 
Figure 2. Kisspeptin-10 (1nM, 10nM, 100nM) stimulation of basal LHRH secretion 
from in-vitro hypothalamic explants. The positive control was aCSF containing 56nM 
K+. Significance is indicated by * p<0.05, ***p< 0.001 vs aCSF control. n=16-
22/group. 
 
Figure 3(i). The effect of peripheral (i.p.) saline (0), kisspeptin-10 (10, 30, 100nmol) 
or 30nmol LHRH at 20 mins following injection on plasma levels of (A) LH, (B) FSH 
and (C) total testosterone in male Wistar rats. Significance is indicated by * p<0.05 vs 
saline control. n= 9-11/group. 
 
Figure 3(ii). The effect of peripheral (i.p.) saline (0), kisspeptin-10 (10, 30, 100nmol) 
or 30nmol LHRH at 60 mins following injection on plasma levels of (A) LH, (B) FSH 
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and (C) total testosterone in male Wistar rats. Significance is indicated by * p<0.05 vs 
saline control. n= 8-10/group. 
 
Figure 4. (A) The effects of i.c.v. kisspeptin-10 (0.3, 1, 3nmol), saline (control) or 
NPY (5nmol) on food intake in ad libitum fed rats in the early light phase in the first 2 
hrs following injection. n= 8-11/group. (B) The effects of i.c.v. kisspeptin-10 (0.3, 1, 
3nmol), saline (control) or NPD-MSH (3nmol) on food intake in overnight fasted rats 
in the early phase in the first 2 hrs following injection. n=8-10/group. (C) The effects 
of i.c.v. kisspeptin-10 (3nmol), saline (control) or NDP-MSH (3nmol) on food intake 
in ad libitum fed rats in the early dark phase in the first 2 hrs following injection. n=8-
10/group. Significance is indicated by *P < 0.05. 
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Table 1 
Behaviour over the first 1 hr following i.c.v. injection of kisspeptin-10 (3nmol) or 
saline. 
 
% of time spent in a behaviour (interquartile range) 
 Saline  Kisspeptin (3nmol) 
Feeding 0 (0- 8.3) 0 (0- 6.3) 
Drinking 0 (0- 0) 0 (0- 0) 
Grooming 13.9 (8.3- 16.7) 2.8 (0- 9.0) 
Rearing 19.4 (8.3- 22.2) 5.6 (2.8- 13.2) 
Locomotion 5.6 (5.6- 9.7) 12.5 (9.7- 15.3) 
Head down 16.7 (11.1- 22.2) 16.7 (10.4- 18.1) 
Sleeping 50 (33.3- 50) 50 (37.5- 70.1) 
 
Rats (n=7-8/group) were i.c.v. injected with 3nmol kisspeptin-10 or saline. Results are 
expressed as the median percentage (interquartile range) of the total time of 
observation spent in a particular behaviour.   
 
 
 
Table 2 
The effect of kisspeptin-10 on release of peptides from in-vitro hypothalamic 
explants. 
 
  
Basal 
 
Kisspeptin 
1nM 
 
Kisspeptin 
10nM 
 
Kisspeptin 
100nM 
 
Potassium 
56mM 
 
Oxytocin 
 
100 
(± 13) 
 
105 
(± 29) 
 
81 
(± 26) 
 
131 
(± 22) 
 
222  
(± 10) 
 
Galanin 
 
100 
(± 13) 
 
81 
(±14) 
 
97.6 
(± 17) 
 
101 
(± 22) 
 
120  
(± 14) 
 
All values are expressed as a percentage of the basal release ± SEM, n=13-22/group. 
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Table 3 
The effect of kisspeptin-10 on the release of gonadotropins from in-vitro anterior 
pituitary fragments. 
  
Basal 
 
Kisspeptin 
100nmol 
 
Kisspeptin 
1000nmol 
 
LHRH 
100nmol 
 
LH 
 
 
100 
(± 11.1) 
 
95 
(± 7.4) 
 
96 
(± 7.7) 
 
188.5 *** 
(± 8.3) 
 
FSH 
 
 
100 
(± 8.4) 
 
-------- 
 
88 
(± 6.7) 
 
146 * 
(± 9.8) 
 
All values are expressed as a percentage of the basal release ± SEM. Significance is 
indicated by     * p<0.05, *** p<0.001 vs basal release. n=24/group 
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